Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Harvard Business School
Boehringer Ingelheim
Express Scripts
Merck

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,513,223


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,513,223 protect, and when does it expire?

Patent 8,513,223 protects SEYSARA and is included in one NDA.

This patent has fourteen patent family members in twelve countries.

Summary for Patent: 8,513,223
Title:Substituted tetracycline compounds for treatment of inflammatory skin disorders
Abstract: Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described.
Inventor(s): Assefa; Haregewein (Braintree, MA), Bhatia; Beena (Mansfield, MA), Draper; Michael P. (Windham, NH), Honeyman; Laura (London, CA), Kim; Oak (Cambridge, MA), Molnar; Dennis P. (Hopkinton, MA)
Assignee: Paratek Pharmaceuticals, Inc. (Boston, MA)
Application Number:11/963,509
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,513,223

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-001 Oct 1, 2018 RX Yes No   Start Trial   Start Trial A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE   Start Trial
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-002 Oct 1, 2018 RX Yes No   Start Trial   Start Trial A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE   Start Trial
Almirall SEYSARA sarecycline hydrochloride TABLET;ORAL 209521-003 Oct 1, 2018 RX Yes Yes   Start Trial   Start Trial A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,513,223

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2007338681   Start Trial
Canada 2673486   Start Trial
Canada 2892739   Start Trial
Cyprus 1121135   Start Trial
Denmark 2120963   Start Trial
European Patent Office 2120963   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Mallinckrodt
AstraZeneca
Colorcon
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.